Headache and Migraine

Treatment with INP104 was associated with high rates of symptoms freedom and may be a promising new acute treatment for patients with migraine.

Experts were in agreement that the criteria should include PTH phenotype, TBI mechanism and TBI comorbidities.

The nasal delivery of dihydroergotamine also showed a lower incidence of nausea than IV-administrated dihydroergotamine.

Rimegepant (Nurtec ODT; Biohaven) had the lowest number needed to treat for sustained pain freedom from migraine.

More than 80% of participants experienced at least 50% reduction in monthly migraine days, while more than 60% and just under 50% experienced at least 75% and 100% reductions.

With the AHS 63rd Annual Scientific Meeting set to kick-off virtually on June 3, 2021, Jessica Ailani, MD, FAHS, offered her perspective on what to expect from the presentations and sessions.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 28, 2021.

Biohaven’s agent is now the first oral CGRP antagonist to be approved for prevention, and the first to be approved for both acute and preventive therapy. It is marketed as Nurtec ODT and is administered in a 75-mg dose.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the role of clinicians in determining migraine treatment eligibility.

What physicians in the community need to know about treating patients with migraine in community settings, and resources that can help locate certified headache specialists or other migraine specialists for referral.

Various ways health care professionals can become involved in migraine advocacy, and tips that can be used in the clinic to support patients.

Lawrence Severt, MD, PhD, discussed the history of CGRP antagonists and what atogepant can potentially bring to the market pending approval.

Here's what is coming soon to NeurologyLive.

A recent paper supported by several presentations at AAN 2021 elucidate areas of migraine care to improve.

Neurology News Network for the week ending May 22, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 21, 2021.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed the barriers to the use of preventive medicines.

Considerations for addressing current limitations in the diagnosis and management of migraine in black, indigenous, and people of color.

Reactions to advances in migraine treatment, specifically with the development of disease-specific targeted therapies.

Migraine with aura was associated with the risk of incident hypertension and no significant difference was observed between individuals with or without aura.

The associate professor and director of the Headache Medicine Fellowship Program at Thomas Jefferson University discussed treatment optimization for patients with migraine and raising overall awareness for preventive treatments.

Acute encephalopathy, coma, and stroke were among clinically diagnosed neurological symptoms that increased mortality risk in patients with COVID-19.

The study will be based in West Haven, Connecticut, and enroll up to 100 veterans with the headache disorder.

Nearly 65% of responders say their migraine disease makes them feel like life is passing them by and more than half claimed they cannot make plans with friends or family because of the unpredictability of their disease.